Andrew Peller, Algoma Central, Argo Graphene at 52-Week Highs on NewsBaystreet·1 day ago, 10:21 AMCRDL+4.17%BNS-1.80%
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis TrialMarket Beat·Aug 12 at 07:01 AMCRDL+4.17%
CRDL: Phase III trial of an oral therapy for recurrent pericarditis nears readout, with broad commercial ambitionsQuartr·Aug 11 at 09:51 AMCRDL+4.17%
Cardiol Therapeutics to join Canaccord Genuity Growth Conference fireside chatPUBT·Aug 5 at 06:27 AMCRDL+4.17%
First Berlin reiterates Buy on Cardiol Therapeutics, keeps USD 7.5 target pricePUBT·Jul 20 at 09:41 AMCRDL+4.17%
H.C. Wainwright Remains a Buy on Cardiol Therapeutics (CRDL)Tip Ranks·Jul 14 at 11:15 AMCRDL+4.17%RANK-2.22%
Cardiol Therapeutics says Phase II recurrent pericarditis data for CardiolRx published in JAHAPUBT·Jul 14 at 06:27 AMCRDL+4.17%
07:27 ETCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summitprnewswire·Jul 9 at 06:28 AMCRDL+4.17%
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | CRDL Stock NewsStockTitan·Jun 24 at 10:27 PMCRDL+4.17%
